Bibliography:
1. Wamboldt R, Haseeb S, Waddington A, Baranchuk A. Cardiac arrhythmias
secondary to hormone therapy in trans women. Expert Rev Cardiovasc Ther
[Internet]. 2019;17(5):335–43. Available from:
https://doi.org/10.1080/14779072.2019.1606713
2. Sedlak T, Shufelt C, Iribarren C, Merz CNB. Sex hormones and the QT
interval: A review. J Women’s Heal. 2012;21(9):933–41.
3. Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin
JP. Sex differences in ventricular repolarization: From cardiac
electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol.
2004;18(2):139–51.
4. Kwong JCC, Krakowsky Y, Grober E. Testosterone Deficiency: A Review
and Comparison of Current Guidelines. J Sex Med [Internet].
2019;16(6):812–20. Available from:
https://doi.org/10.1016/j.jsxm.2019.03.262
5. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms
and treatment. J Adv Pharm Technol Res. 2010;1(3):297–301.
6. Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and
Cardiovascular Disease. J Am Coll Cardiol. 2016;67(5):545–57.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al.
Preferred reporting items for systematic reviews and meta-analyses: The
PRISMA statement. PLoS Med. 2009;6(7).
8. Schwartz JB, Volterrani M, Caminiti G, Marazzi G, Fini M, Rosano GMC,
et al. Effects of testosterone on the Q-T Interval in older men and
older women with chronic heart failure. Int J Androl. 2011;34(5 PART
2):415–21.
9. Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E,
et al. Sex-steroid hormones and electrocardiographic qt-interval
duration: Findings from the third national health and nutrition
examination survey and the multi-ethnic study of atherosclerosis. Am J
Epidemiol. 2011;174(4):403–11.
10. Hiremath PG, Bhondoekhan F, Haberlen SA, Ashikaga H, Palella FJ,
D’Souza G, et al. Testosterone use and shorter electrocardiographic QT
interval duration in men living with and without HIV. HIV Med.
2020;1–4.
11. Vicente J, Simlund J, Johannesen L, Sundh F, Florian J, Ugander M,
et al. Investigation of potential mechanisms of sex differences in
quinidine-induced torsade de pointes risk. J Electrocardiol
[Internet]. 2015;48(4):533–8. Available from:
http://dx.doi.org/10.1016/j.jelectrocard.2015.03.011
12. Barber M, Nguyen LS, Wassermann J, Spano JP, Funck-Brentano C, Salem
JE. Cardiac arrhythmia considerations of hormone cancer therapies.
Cardiovasc Res. 2019;115(5):878–94.
13. Haque R, Ulcickasyood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating
NL, et al. Cardiovascular disease risk and androgen deprivation therapy
in patients with localised prostate cancer: A prospective cohort study.
Br J Cancer [Internet]. 2017;117(8):1233–40. Available from:
http://dx.doi.org/10.1038/bjc.2017.280
14. Lazzerini PE, Bertolozzi I, Acampa M, Cantara S, Castagna MG,
Pieragnoli L, et al. Androgen Deprivation Therapy for Prostatic Cancer
in Patients With Torsades de Pointes. Front Pharmacol.
2020;11(May):1–11.
15. Gheorghe ACD, Ciobanu A, Hodorogea AS, Radavoi GD, Jinga V, Nanea
IT, et al. Evolution of Electrocardiographic Repolarization Parameters
During Antiandrogen Therapy in Patients with Prostate Cancer and
Hypogonadism. Cardiovasc Toxicol [Internet]. 2020;20(4):390–400.
Available from: https://doi.org/10.1007/s12012-020-09566-6
16. Belderbos BPSI, de Wit R, Chien C, Mitselos A, Hellemans P, Jiao J,
et al. An open-label, multicenter, phase Ib study investigating the
effect of apalutamide on ventricular repolarization in men with
castration-resistant prostate cancer. Cancer Chemother Pharmacol
[Internet]. 2018;82(3):457–68. Available from:
http://dx.doi.org/10.1007/s00280-018-3632-6
17. Salem JE, Bretagne M, Lebrun-Vignes B, Waintraub X, Gandjbakhch E,
Hidden-Lucet F, et al. Clinical characterization of men with long QT
syndrome and torsades de pointes associated with hypogonadism: A review
and pharmacovigilance study. Arch Cardiovasc Dis [Internet].
2019;112(11):699–712. Available from:
https://doi.org/10.1016/j.acvd.2019.06.008
18. Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano
C, Pariente A, et al. Increased long QT and torsade de pointes reporting
on tamoxifen compared with aromatase inhibitors. Heart. 2018;1–5.
19. Abehsira G, Bachelot A, Badilini F, Koehl L, Lebot M, Favet C, et
al. Complex influence of gonadotropins and sex steroid hormones on QT
interval duration. J Clin Endocrinol Metab. 2016;101(7):2776–84.
20. JØrgensen IN, SkakkebÆk A, Andersen NH, Pedersen LNø, Hougaard DM,
Bojesen A, et al. Short QTc interval in males with klinefelter syndrome
- Influence of CAG repeat length, body composition, and testosterone
replacement therapy. PACE - Pacing Clin Electrophysiol.
2015;38(4):472–82.
21. Pecori Giraldi F, Toja PM, Filippini B, Michailidis J, Scacchi M,
Stramba Badiale M, et al. Increased prevalence of prolonged QT interval
in males with primary or secondary hypogonadism: A pilot study. Int J
Androl. 2010;33(1).
22. Bidoggia H, Maciel JP, Capalozza N, Mosca S, Blaksley EJ, Valverde
E, et al. Sex differences on the electrocardiographic pattern of cardiac
repolarization: Possible role of testosterone. Am Heart J.
2000;140(4):678–83.
23. Giraldi FP, Manzoni G, Michailidis J, Scacchi M, Stramba-Badiale M,
Cavagnini F. High prevalence of prolonged qt interval in obese
hypogonadal males. Obesity [Internet]. 2011;19(10):2015–8.
Available from: http://dx.doi.org/10.1038/oby.2011.33/nature06264
24. Charbit B, Christin-Maître S, Démolis JL, Soustre E, Young J,
Funck-Brentano C. Effects of Testosterone on Ventricular Repolarization
in Hypogonadic Men. Am J Cardiol [Internet]. 2009;103(6):887–90.
Available from: http://dx.doi.org/10.1016/j.amjcard.2008.11.041
25. Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, et al.
Effect of cirrhosis and liver transplantation on the gender difference
in QT interval. Am J Cardiol. 2005;95(5):691–4.
26. Vrtovec B, Meden-Vrtovec H, Jensterle M, Radovancevic B.
Testosterone-related shortening of QTc interval in women with polycystic
ovary syndrome. J Endocrinol Invest. 2008;31(7):653–5.
27. Gazi E, Gencer M, Hanci V, Temiz A, Altun B, Güngör ANÇ, et al.
Polikistik over sendromu olan genç kadi{dotless}nlarda QT dispersiyonu
ile gonadal hormonlar ve insulin arasi{dotless}ndaki ilişki: Gözlemsel
bir çali{dotless}şma. Anadolu Kardiyol Derg. 2013;13(8):772–7.
28. Pecori Giraldi F, Toja PM, Michailidis G, Metinidou A, De Martin M,
Scacchi M, et al. High prevalence of prolonged qt interval duration in
male patients with Cushing’s disease. Exp Clin Endocrinol Diabetes.
2011;119(4):221–4.
29. Kirilmaz A, Bolu E, Kilicaslan F, Erinc K, Uzun M, Isik E, et al.
Comparison of electrocardiographic repolarization patterns between
hypogonad males and normal subjects. Ann Noninvasive Electrocardiol.
2003;8(4):284–8.
30. La Fountaine MF, Wecht JM, Cirnigliaro CM, Kirshblum SC, Spungen AM,
Bauman WA. Testosterone replacement therapy improves QTaVI in
hypogonadal men with spinal cord injury. Neuroendocrinology.
2013;97(4):341–6.
31. Lubart E, Yarovoy A, Gal G, Krakover R, Leibovitz A. QT interval
length in elderly prostatic cancer patients on anti-testosterone
treatment. Isr Med Assoc J. 2015;17(6):356–8.
32. Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of
Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the
Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised,
Placebo and Active Comparator Controlled Thorough QT/QTc Trial in
Healthy Men. Clin Drug Investig. 2017;37(9):873–9.
33. Zhao J, Jiang C, Lam TH, Liu B, Cheng KK, Xu L, et al. Genetically
predicted testosterone and electrocardiographic QT interval duration in
Chinese: A Mendelian randomization analysis in the Guangzhou Biobank
Cohort Study. Int J Epidemiol. 2015;44(2):613–20.
34. Gagliano-Juca T, Betulçli T, Pencina KM, Li Z, Tapper J, Huang G, et
al. Effects of testosterone replacement on electrocardiographic
parameters in men: Findings from two randomized trials. J Clin
Endocrinol Metab. 2017;102(5):1478–85.
35. Gagliano-Jucá T, Travison TG, Kantoff PW, Nguyen PL, Taplin ME,
Kibel AS, et al. Androgen deprivation therapy is associated with
prolongation of QTc interval inmen with prostate cancer. J Endocr Soc.
2018;2(5):485–96.
36. Huo J, Wei F, Cai C, Lyn-Cook B, Pang L. Sex-Related Differences in
Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System
with Human iPSC-CMs. Toxicol Sci. 2019;167(2):360–74.
37. La Fountaine MF, Wecht JM, Cirnigliaro CM, Kirshblum SC, Spungen AM,
Bauman WA. QT/RR coherence is associated with testosterone levels in men
with chronic spinal cord injury. Neuroendocrinology. 2011;93(3):174–80.
38. Piccirillo G, Moscucci F, Pofi R, D’Alessandro G, Minnetti M,
Isidori AM, et al. Changes in left ventricular repolarization after
short-term testosterone replacement therapy in hypogonadal males. J
Endocrinol Invest [Internet]. 2019;42(9):1051–65. Available from:
https://doi.org/10.1007/s40618-019-01026-5
39. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E,
Maupain C, et al. Hypogonadism as a reversible cause of torsades de
pointes in men. Circulation. 2018;138(1):110–3.
40. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot
A, et al. Androgenic effects on ventricular repolarization a
translational study from the international pharmacovigilance database to
iPSC-cardiomyocytes. Circulation. 2019;140(13):1070–80.
41. Vicente J, Johannesen L, Galeotti L, Strauss DG. Mechanisms of sex
and age differences in ventricular repolarization in humans. Am Heart J
[Internet]. 2014;168(5):749-756.e3. Available from:
http://dx.doi.org/10.1016/j.ahj.2014.07.010
42. Wu ZY, Chen K, Haendler B, McDonald T V., Bian JS. Stimulation of
N-terminal truncated isoform of androgen receptor stabilizes human
ether-á-go-go-related gene-encoded potassium channel protein via
activation of extracellular signal regulated kinase 1/2. Endocrinology.
2008;149(10):5061–9.
43. Valverde ER, Biagetti MO, Bertran GR, Arini PD, Bidoggia H,
Quinteiro RA. Developmental changes of cardiac repolarization in
rabbits: Implications for the role of sex hormones. Cardiovasc Res.
2003;57(3):625–31.
44. Liu XK, Katchman A, Whitfield BH, Wan G, Janowski EM, Woosley RL, et
al. In vivo androgen treatment shortens the QT interval and increases
the densities of inward and delayed rectifier potassium currents in
orchiectomized male rabbits. Cardiovasc Res. 2003;57(1):28–36.
45. Alexandre J, Milliez P, Rouet R, Manrique A, Allouche S, Piccirillo
G, et al. Aldosterone and testosterone: Two steroid hormones
structurally related but with opposite electrophysiological properties
during myocardial ischemia-reperfusion. Fundam Clin Pharmacol.
2015;29(4):341–51.
46. Lujan HL, Kramer VJ, Dicarlo SE. Sex influences the susceptibility
to reperfusion-induced sustained ventricular tachycardia and
β-adrenergic receptor blockade in conscious rats. Am J Physiol - Hear
Circ Physiol. 2007;293(5).
47. Masuda K, Takanari H, Morishima M, Ma FF, Wang Y, Takahashi N, et
al. Testosterone-mediated upregulation of delayed rectifier potassium
channel in cardiomyocytes causes abbreviation of QT intervals in rats. J
Physiol Sci [Internet]. 2018;68(6):759–67. Available from:
https://doi.org/10.1007/s12576-017-0590-4
48. Brouillette J, Rivard K, Lizotte E, Fiset C. Sex and strain
differences in adult mouse cardiac repolarization: Importance of
androgens. Cardiovasc Res. 2005;65(1):148–57.
49. Brouillette J, Trépanier-Boulay V, Fiset C. Effect of androgen
deficiency on mouse ventricular repolarization. J Physiol.
2003;546(2):403–13.
50. Crump SM, Hu Z, Kant R, Levy DI, Goldstein SAN, Abbott GW. Kcne4
deletion sex- and age-specifically impairs cardiac repolarization in
mice. FASEB J. 2016;30(1):360–9.
51. Hu Z, Wei W, Zhou L, Chen M, Abbott GW. Kcne4 deletion
sex-specifically predisposes to cardiac arrhythmia via
testosterone-dependent impairment of RISK/SAFE pathway induction in aged
mice. Sci Rep. 2018;8(1):1–14.
52. Sun YL, Li PH, Shi L, Su WZ, Li DS, Xue GL, et al. Valsartan reduced
the vulnerability to atrial fibrillation by preventing action potential
prolongation and conduction slowing in castrated male mice. J Cardiovasc
Electrophysiol. 2018;29(10):1436–43.
53. Tsai WC, Lu YY, Chen YC, Chang CJ, Kao YH, Lin YK, et al. Ablation
of androgen receptor gene triggers right ventricular outflow tract
ventricular tachycardia. Int J Cardiol [Internet].
2015;189(1):172–81. Available from:
http://dx.doi.org/10.1016/j.ijcard.2015.04.080
54. Tsai WC, Yang LY, Chen YC, Kao YH, Lin YK, Chen SA, et al. Ablation
of the androgen receptor gene modulates atrial electrophysiology and
arrhythmogenesis with calcium protein dysregulation. Endocrinology.
2013;154(8):2833–42.
55. Zhang Y, Wang HM, Wang YZ, Zhang YY, Jin XX, Zhao Y, et al.
Increment of late sodium currents in the left atrial myocytes and its
potential contribution to increased susceptibility of atrial
fibrillation in castrated male mice. Hear Rhythm [Internet].
2017;14(7):1073–80. Available from:
http://dx.doi.org/10.1016/j.hrthm.2017.01.046
56. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex
hormones prolong the QT interval and downregulate potassium channel
expression in the rabbit heart. Circulation. 1996;94(6):1471–4.
57. Lang CN, Menza M, Jochem S, Franke G, Perez Feliz S, Brunner M, et
al. Electro-mechanical dysfunction in long QT syndrome: Role for
arrhythmogenic risk prediction and modulation by sex and sex hormones.
Prog Biophys Mol Biol [Internet]. 2016;120(1–3):255–69. Available
from: http://dx.doi.org/10.1016/j.pbiomolbio.2015.12.010
58. Pham T V., Robinson RB, Danilo P, Rosen MR. Effects of gonadal
steroids on gender-related differences in transmural dispersion of
L-type calcium current. Cardiovasc Res. 2002;53(3):752–62.
59. Pham T V., Sosunov EA, Gainullin RZ, Danilo P, Rosen MR. Impact of
sex and gonadal steroids on prolongation of ventricular repolarization
and arrhythmias induced by Ik-blocking drugs. Circulation.
2001;103(17):2207–12.
60. Pham T V., Sosunov EA, Anyukhovsky EP, Danilo P, Rosen MR.
Testosterone diminishes the proarrhythmic effects of dofetilide in
normal female rabbits. Circulation. 2002;106(16):2132–6.
61. Argenziano M, Tiscornia G, Moretta R, Casal L, Potilinski C, Amorena
C, et al. Arrhythmogenic effect of androgens on the rat heart. J Physiol
Sci. 2017;67(1):217–25.
62. Ayaz M, Akand M, Kucukbagriacik Y, Dursunoglu D. The effects of
estradiol on cardiac muscle electrophysiology in orchiectomized rat
model: A new insight to side effects caused by castration. Eur Rev Med
Pharmacol Sci. 2015;19(15):2866–74.
63. Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NMK, Alkhateeb M.
Effect of testosterone replacement therapy on cardiac performance and
oxidative stress in orchidectomized rats. Acta Physiol.
2013;209(2):136–47.
64. Shuba YM, Degtiar VE, Osipenko VN, Naidenov VG, Woosley RL.
Testosterone-mediated modulation of HERG blockade by proarrhythmic
agents. Biochem Pharmacol. 2001;62(1):41–9.
65. Barajas-Martinez H, Haufe V, Chamberland C, Roy MJB, Fecteau MH,
Cordeiro JM, et al. Larger dispersion of INa in female dog ventricle as
a mechanism for gender-specific incidence of cardiac arrhythmias.
Cardiovasc Res. 2009;81(1):82–9.
66. Fülöp L, Bányász T, Szabó G, Tóth IB, Bíró T, Lôrincz I, et al.
Effects of sex hormones on ECG parameters and expression of cardiac ion
channels in dogs. Acta Physiol. 2006;188(3–4):163–71.
67. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T.
Nontranscriptional regulation of cardiac repolarization currents by
testosterone. Circulation. 2005;112(12):1701–10.
68. James AF, Arberry LA, Hancox JC. Gender-related differences in
venticular myocyte repolarization in the guinea pig. Basic Res Cardiol.
2004;99(3):183–92.
69. Yang PC, Kurokawa J, Furukawa T, Clancy CE. Acute effects of sex
steroid hormones on susceptibility to cardiac arrhythmias: A simulation
study. PLoS Comput Biol. 2010;6(1).
70. Raghu KG, Singh R, Prathapan A, Yadav GK. Modulation of haloperidol
induced electrophysiological alterations on cardiac action potential by
various risk factors and gender difference. Chem Biol Interact.
2009;180(3):454–9.
71. Argenziano M, Tiscornia G, Moretta R, Amorena CE, Gras EG. Control
hormonal de las corrientes de la fase 1 del potencial de acción cardíaco
en el síndrome de Brugada. Rev Argent Cardiol. 2014;82(4):292–7.
72. Muensterman ET, Jaynes HA, Sowinski KM, Overholser BR, Shen C,
Kovacs RJ, et al. Effect of transdermal testosterone and oral
progesterone on drug-induced QT interval lengthening in older men a
randomized, double-blind, placebo-controlled crossover-design study.
Circulation. 2019;140(13):1127–9.
73. Tsai WC, Lee TI, Chen YC, Kao YH, Lu YY, Lin YK, et al. Testosterone
replacement increases aged pulmonary vein and left atrium
arrhythmogenesis with enhanced adrenergic activity. Int J Cardiol
[Internet]. 2014;176(1):110–8. Available from:
http://dx.doi.org/10.1016/j.ijcard.2014.06.054
74. Van Noord C, Eijgelsheim M, Stricker BHC. Drug- and
non-drug-associated QT interval prolongation. Br J Clin Pharmacol.
2010;70(1):16–23.
75. College of Physicians and Surgeons of British Columbia. Drug
Associated with QT Interval Prolongation. 2003; Available from:
https://www.cpsbc.ca/files/pdf/Methadone-Drugs-QT-Interval-Prolongation.pdf
76. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval
prolongation: Mechanisms and clinical management. Ther Adv Drug Saf.
2012;3(5):241–53.
77. Cheng J. Evidences of the gender-related differences in cardiac
repolarization and the underlying mechanisms in different animal species
and human. Fundam Clin Pharmacol. 2006;20(1):1–8.
78. Drug F, Bulletin T. QT interval and drug therapy. BMJ.
2016;353(June):1–5.
79. Lapointe NMA, Kramer JM, Califf RM. About the QT Interval.
2003;289(16).